BioSpace18h
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes
The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...
pharmaphorum19h
Australia stands firm on 'no' to Alzheimer's drug Leqembi
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
STAT17h
Pharmalittle: We’re reading about HHS reducing public comment, a Lilly obesity drug ad, and more
HHS Secretary Robert F. Kennedy Jr. is proposing to strip public participation from much of the business his agency conducts ...
Drugmaker Eisai will cut 57 jobs at North Jersey headquarters
Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S workforce.
FiercePharma3d
CHMP again backs Leqembi amid flurry of approval recommendations
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...
Reuters4d
Eisai Co Ltd
EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen ...